Pfizer says no new serious adverse events in DMD gene therapy trial - (National Post via NewsPoints Desk)

  • Pfizer administered doses of its experimental gene therapy for Duchenne muscular dystrophy to an additional nine boys, and says no serious adverse events have been observed, as reported in the National Post.

  • Seng Cheng, chief scientific officer of Pfizer's rare disease unit, said the company plans to start a pivotal trial on the gene therapy in ambulatory patients in the next several weeks.

  • The drugmaker had modified the regimen for the gene therapy earlier this year after three patients had to be hospitalized.

To read more NewsPoints articles, click here.